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ABSTRACT: Two new bifunctional tris(hydroxypyridinone)
(THP) chelators designed speciﬁcally for rapid labeling with 68Ga
have been synthesized, each with pendant isothiocyanate groups
and three 1,6-dimethyl-3-hydroxypyridin-4-one groups. Both
compounds have been conjugated with the primary amine group
of a cyclic integrin targeting peptide, RGD. Each conjugate can be
radiolabeled and formulated by treatment with generator-produced
68Ga3+ in over 95% radiochemical yield under ambient conditions
in less than 5 min, with speciﬁc activities of 60−80 MBq nmol−1.
Competitive binding assays and in vivo biodistribution in mice bearing U87MG tumors demonstrate that the new 68Ga3+-labeled
THP peptide conjugates retain aﬃnity for the αvβ3 integrin receptor, clear within 1−2 h from circulation, and undergo receptor-
mediated tumor uptake in vivo. We conclude that bifunctional THP chelators can be used for simple, eﬃcient labeling of 68Ga
biomolecules under mild conditions suitable for peptides and proteins.
■ INTRODUCTION
The generator-produced positron-emitting isotope gallium-68
(68Ga) possesses a decay proﬁle (t1/2 = 68 min, 90% positron
yield, 1.9 MeV) that makes it suitable for molecular imaging
with positron emission tomography (PET) using peptide-based
targeting agents.1−3 The advent of an approved pharmaceutical
grade 68Ge/68Ga generator3 (68Ge t1/2 = 270 days) allows
hospitals economical access to a PET isotope without expensive
cyclotron facilities. Indeed, current clinical use of 68Ga tracers
for neuroendocrine (68Ga-DOTATATE) and prostate (68Ga-
HBED-PSMA) tumor-targeting radiopharmaceuticals has had
signiﬁcant impact in the management of patients.4−9
The macrocycle 1,4,7,10-tetraazacyclododecane-1,4,7,10-tet-
raacetic acid (DOTA), utilized in 68Ga-DOTATATE, has been
extensively used in radiolabeled 68Ga3+ PET tracers despite the
fact that elevated temperatures are required to achieve
quantitative radiochemical yield, and some clinical productions
of 68Ga-DOTATATE require a postsynthetic puriﬁcation
step1,2,10−12 which adds undesirable complexity to the radio-
pharmaceutical preparation, creating a barrier to widespread
implementation of 68Ga PET. To allow for simpliﬁcation of
labeling, alternative bifunctional chelators for 68Ga3+ have been
designed. These include bifunctional chelators based on 1,4,7-
triazacyclononane-1,4,7-triacetic acid (NOTA and NODA-
GA),13−20 1,4,7-triazacyclononane macrocycles substituted
with phosphinic acid groups at the amine (TRAP and
NOPO),21−27 hexaazamacrobicycles,28 a pyridyl-substituted
DOTA macrocycle (PCTA),10,29 bis(2-hydroxybenzyl)-
ethylenediaminediacetic acid (HBED), and related compounds
(notably HBED-CC) possessing phenol, amine, and carboxyl
donor groups,4,30 substituted 6-amino-perhydrodiazepines
(AAZTA),31 a siderophore-derived macrocyclic chelator with
hydroxamate groups (FSC),32 and an acyclic chelator based on
a substituted pyridine carboxylate with an N4O2 binding mode
(DEDPA).33−35 Derivatives of NOTA/NODAGA, TRAP/
NOPO, HBED, FSC, AAZTA, and DEDPA conjugates have
demonstrated desirable radiolabeling properties, with labeling
proceeding at room temperature for all these chelators. We
have described a tripodal ligand containing three 1,6-dimethyl-
3-hydroxypyridin-4-one groups (H3THP-Ac) that, upon loss of
three protons, coordinates 68Ga3+ via 6 O-atoms at pH 6−7 and
low ligand concentrations (10 μM) in <5 min (Chart 1).36 This
chelator can be radiolabeled quantitatively and faster, at lower
chelator concentration and under conditions that are milder36
(ambient temperature without acidic pH) than other chelators
such as DOTA and NOTA that are commonly employed for
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68Ga3+ and that typically require acidic conditions (pH 2−5)
and, in the case of DOTA, high temperatures (≥80 °C) to
achieve quantitative labeling.10−13 A maleimide derivative of
this chelator (for conjugation to thiol groups) has been
prepared (H3THP-mal, Chart 1),
36,37 68Ga-labeled conjugates
of which demonstrated high in vivo stability over 90 min with
respect to metal complex integrity.
To increase the versatility of this unique chelation system to
enable labeling of noncysteine-containing biomolecules, includ-
ing small proteins and antibodies, new derivatives are required.
We report the synthesis of two new tris(hydroxypyridinone)
chelators based on 1,6-dimethyl-3-hydroxypyridin-4-one groups
that contain pendant isothiocyanates for conjugation to primary
amines, and their use for labeling exemplar peptide conjugates
with 68Ga for PET imaging.
■ RESULTS
Synthesis and Radiolabeling of Peptide Conjugates.
To synthesize H3THP-NCS (Scheme 1), (1)
38 was reacted
with triethylamine and carbon disulﬁde in ethanol, to give a
precipitated dithiocarbamate intermediate upon addition of
water.39 The precipitated intermediate was resuspended in a
solution of carbon disulﬁde/ethanol and addition of di-tert-
butyl dicarbonate and a catalytic amount of 4-dimethylamino-
pyridine resulted in formation of (2). Subsequent removal of
the benzyl groups with boron trichloride in dichloromethane,
followed by addition of triﬂuoroethanol resulted in H3THP-
NCS. To synthesize H3THP-PhNCS (Scheme 1), an excess of
p-phenylene diisothiocyanate and diisopropylethylamine in
dimethylformamide were added to a solution of (1), followed
by isolation of (3) using reverse-phase semipreparative high-
performance liquid chromatography (HPLC). The benzyl
groups of (3) were removed using boron trichloride in
dichloromethane, followed by addition of methanol, resulting
in the bifunctional chelator H3THP-PhNCS.
The αvβ3 integrin-targeting pentapeptide, cyclic(RGDfK)
(RGD), was chosen as an appropriately well-characterized
peptide targeting vector40 for conjugation to the new
tris(hydroxypyridinone) bifunctional chelators. Both H3THP-
NCS and H3THP-PhNCS were reacted with the primary amine
of the lysine side chain of RGD under microwave conditions
similar to those often employed for peptide synthesis (dimethyl
sulfoxide containing diisopropylethylamine, 120 °C, 300 W, 30
min). Use of dimethylformamide as a solvent in place of
dimethyl sulfoxide resulted in precipitation of the bifunctional
chelator upon addition of base, and no reaction took place,
necessitating the use of dimethyl sulfoxide as a solvent. The
reaction products were puriﬁed using semipreparative HPLC.
Both conjugates H3THP-NCS-RGD and H3THP-PhNCS-
RGD (Figure 1a,c) were isolated in 98% purity.
Both peptide derivatives could be radiolabeled with
generator-produced eluate that was added either directly from
the generator, or eluate that was preconditioned to concentrate
activity and remove any contaminating 68Ge. In the case of the
former, addition of generator-produced 68Ga3+ (90−110 MBq,
Eckert and Ziegler generator) in aqueous HCl (0.1 M, 1 mL) to
the tris(hydroxypyridinone) conjugates (10−12 nmol) at
ambient temperature, followed by addition of aqueous
ammonium acetate (1 M, 300 μL) to obtain solutions of pH
∼ 6.5, provided 68Ga-labeled conjugate. Within 2−5 min of
addition of 68Ga3+ to the conjugates, the solutions were
subjected to analytical reverse-phase HPLC analysis. Each
reaction mixture gave a single peak in the HPLC radio-
chromatogram (Figure 1b,d, red traces), and in these
experiments, in which a low activity generator was utilized,
the radiochemical yield measured >99%, with speciﬁc activities
of 8−9 MBq nmol−1.
For radiolabeling conjugates for in vivo studies, a generator
eluting higher activities was employed, and eluate was subjected
to pretreatment prior to radiolabeling to remove 68Ge.41
Generator-produced 68Ga3+(800−1000 MBq, iThemba Labo-
ratories generator) was concentrated on an AG 50W × 4 cation
exchange cartridge, and eluted with 200 μL 0.9 M HCl in
ethanol/water (90%/10%).41 This volume was diluted in
deionized water (800 μL) and directly added to H3THP-
NCS-RGD and H3THP-PhNCS-RGD (∼12 nmol) at ambient
temperature, followed immediately by addition of aqueous
ammonium acetate (2 M, 400 μL) and saline to obtain
solutions of pH ∼ 6.5, resulting in solutions of [68Ga(THP-
NCS-RGD)] and [68Ga(THP-PhNCS-RGD)]. Within 2−5
min of addition of 68Ga3+ to the conjugates, the solutions were
subjected to analytical reverse-phase HPLC and instant thin
layer chromatography (ITLC) analysis. Each reaction mixture
gave a single major peak in the HPLC radiochromatogram
(Figure S1), and under these conditions, the radiochemical
yield for all of these reactions was >95% (determined by
ITLC), with speciﬁc activities of 60−80 MBq nmol−1.
To verify the identity of the radiolabeled products, the 68Ga-
labeled conjugates and their nonradioactive (natGa) analogs
were analyzed using analytical reverse-phase HPLC with UV
and sodium iodide scintillation detection. H3THP-NCS-RGD
eluted earlier than [nat/68Ga(THP-NCS-RGD)] (Figure 1b,
black trace, retention time of 7.15 min). Co-elution of
Chart 1. Structures of H3THP-Ac and H3-THP-mal
Scheme 1. Synthesis of Tris(hydroxpyridinone) Bifunctional
Chelators Containing Isothiocyanate Groups, H3THP-NCS
(top) and H3THP-PhNCS (bottom)
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[natGa(THP-NCS-RGD)] (Figure 1b, blue trace, retention time
of 7.57 min) with [68Ga(THP-NCS-RGD)] (red trace,
retention time of 7.83 min) conﬁrmed the identity of the
radiolabeled compound, with the diﬀerence in retention time a
result of the conﬁguration of the diﬀerent detectors in series.
Only a single signal was observed in the liquid chromatog-
raphy/mass spectrometry (LCMS) total ion count chromato-
gram, corresponding to [natGa(THP-NCS-RGD)] (Figure 1b,
inset). The dipositive ion ([natGa(THP-NCS-RGD)+2H]2+:
{C65H90N17O17SGa}
2+, observed monoisotopic peak = 740.78,
calculated = 740.78) was the strongest in the spectrum, but the
corresponding tripositive and monopositive species were also
observed. Similarly, a solution containing [natGa(THP-PhNCS-
RGD)] resulted in a signal in the UV chromatogram with a
retention time of 8.15 min, matching that of [68Ga(THP-
PhNCS-RGD)] (8.35 min, radiochromatogram), and distinct
from H3THP-PhNCS-RGD (7.80 min) (Figure 1d). A single
signal was observed in the LCMS total ion count chromato-
gram, corresponding to [natGa(THP-PhNCS-RGD)], and the
major peak in the associated mass spectrum was the dipositive
i o n ( [ n a t G a ( T H P - P h N C S - R G D ) + 2 H ] 2 + :
{C72H96N19O17S2Ga}
2+, observed monoisotopic peak =
815.80, calculated 815.80). No Ga3+ complexes with metal/
ligand stoichiometry other than 1:1 were detected in any
fraction eluting from the HPLC column in either case.
Serum stability studies were undertaken to determine
whether [68Ga(THP-NCS-RGD)] or [68Ga(THP-PhNCS-
RGD)] release 68Ga3+ to endogenous serum proteins. Addition
of generator-produced 68Ga3+ to a solution of human serum
resulted in 68Ga-bound protein and small molecule adducts that
possessed distinct retention times of 5.9, 9.1, and 13.1 min
when applied to the size exclusion HPLC column utilized in
this study (Figure S2a). Under the same conditions, the
radiolabeled peptide conjugates [68Ga(THP-NCS-RGD)] and
[68Ga(THP-PhNCS-RGD)] possessed retention times of 18.1
and 20.2 min, respectively (Figure S2b,d). Both [68Ga(THP-
NCS-RGD)] and [68Ga(THP-PhNCS-RGD)] were incubated
in fresh human serum at 37 °C, and at 1 and 4 h, aliquots of
these serum solutions were applied directly to the size exclusion
HPLC column. Size exclusion chromatograms acquired at 1
and 4 h time points exhibited single signals with the same
retention times as the control samples of [68Ga(THP-NCS-
RGD)] and [68Ga(THP-PhNCS-RGD)], indicating that no
transchelation of 68Ga3+ from peptide conjugate to serum
constituents occurred in either case (Figure S2c,e).
In vivo metabolic stability studies were also performed in
Balb/c mice to assess whether [68Ga(THP-NCS-RGD)] or
[68Ga(THP-PhNCS-RGD)] are modiﬁed, metabolized, or
degraded while in circulation. Blood samples were obtained
20 and 90 min postinjection (PI), the serum fraction was
separated from erythrocytes, serum proteins precipitated, and
the supernatant applied to an analytical reverse-phase HPLC
column. The acquired chromatograms revealed single signals
for each trace, and each signal possessed a retention time that
matched that of the administered radiotracer (Figures S3a-c
and S4a-c). Urine was also collected and analyzed by reverse-
phase HPLC (Figures S3d and S4d). While signals correspond-
ing to the retention time of the administered radiotracers were
observed in the chromatograms for both conjugates, several
other broad signals were observed. These data indicated that
both [68Ga(THP-NCS-RGD)] and [68Ga(THP-PhNCS-
RGD)] were metabolically stable in circulation in vivo over a
period of 90 min; however, renal clearance pathways for both
radiotracers involved signiﬁcant metabolism of both [68Ga-
(THP-NCS-RGD)] and [68Ga(THP-PhNCS-RGD)].
The half-maximal inhibitory concentration (IC50) values of
[Ga(THP-NCS-RGD)], [Ga(THP-PhNCS-RGD)], and RGD
were determined using a solid-phase competitive binding assay
with 125I-echistatin. Binding of 125I-echistatin to αvβ3 integrin
was inhibited by [Ga(THP-NCS-RGD)], [Ga(THP-PhNCS-
RGD)], and RGD in a concentration-dependent manner
demonstrating high binding aﬃnity and speciﬁcity of [Ga-
(THP-NCS-RGD)], [Ga(THP-PhNCS-RGD)], and RGD for
αvβ3 integrin (Table 1, Figure 2). The IC50 value of [Ga(THP-
NCS-RGD)] (8.3 ± 1.5 nM) was comparable to that of RGD
(8.7 ± 1.6 nM), indicating similar aﬃnity for the αvβ3 integrin
receptor. The IC50 value of [Ga(THP-PhNCS-RGD)] (4.8 ±
0.6 nM) was lower than that of [Ga(THP-NCS-RGD)] and
RGD, suggesting a higher relative aﬃnity for the αvβ3 integrin
receptor. Importantly, IC50 values indicated that the tris-
Figure 1. (a) H3THP-NCS-RGD; (b) HPLC traces (λ220) of H3THP-NCS-RGD (black) and [
natGa(THP-NCS-RGD)] (blue), and radio-HPLC
trace of [68Ga(THP-NCS-RGD)] (red). Inset: Mass spectral signal of [natGa(THP-NCS-RGD) + 2H]2+; (c) H3THP-PhNCS-RGD; (d) HPLC
traces (λ220) of H3THP-PhNCS-RGD (black) and [
natGa(THP-PhNCS-RGD)] (blue), and radio-HPLC trace of [68Ga(THP-PhNCS-RGD)] (red).
Inset: Mass spectral signal of [natGa(THP-PhNCS-RGD) + 2H]2+.
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(hydroxypyridinone) conjugates retain the aﬃnity of the parent
peptide for αvβ3 integrin receptors.
Biodistribution of 68Ga-Labeled Peptide Conjugates.
The biodistribution of [68Ga(THP-NCS-RGD)] and [68Ga-
(THP-PhNCS-RGD)] was assessed in Balb/c nu/nu mice
bearing αvβ3 integrin-positive glioblastoma U87MG tumors (n
= 3). Each animal was administered 16−21 MBq of tracer
(containing ∼1 μg of conjugate) and PET scanned at either 1
or 2 h PI for 10 min, followed by euthanasia and organ
harvesting for ex vivo radioactivity counting. To assess
speciﬁcity of the radiotracer, separate groups of animals were
coadministered the tracer and RGD (0.4 mg per animal),
followed by scanning, euthanasia, and ex vivo organ counting 1
h PI.
In PET scans of mice administered [68Ga(THP-NCS-RGD)]
1 h PI (Figure 3a), the tumor was visible, with a tumor to
background (mediastinum) concentration ratio of 2.76 ± 0.18.
The kidneys and liver of all animals were also discernible with a
tumor to kidney concentration ratio of 1.03 ± 0.05, and a
tumor to liver concentration ratio of 1.59 ± 0.16. There was no
evidence of bone uptake being above that of surrounding
muscle. Excretion was largely renal and the bladder was
associated with the highest levels of activity in all PET images.
Images of animals coadministered RGD demonstrated that
RGD eﬀectively blocks αvβ3 integrin receptor binding by
[68Ga(THP-NCS-RGD)].
The ex vivo biodistribution data of [68Ga(THP-NCS-RGD)]
(Figure 3b) were consistent with PET imaging data. In animals
administered solely [68Ga(THP-NCS-RGD)], there was
signiﬁcantly higher radioactivity concentration in the tumor
than in animals co-administered [68Ga(THP-NCS-RGD)] and
RGD, indicative of receptor-mediated tumor uptake (2.35 ±
0.06%ID g−1, vs 0.62 ± 0.10%ID g−1, respectively, mean
diﬀerence = 1.73%ID g−1, 95% CI = 1.45 − 1.99%ID g−1, p =
6.00 × 10−5. Coadministration of RGD also signiﬁcantly
reduced uptake of the tracer at 1 h PI in the heart, liver, spleen,
muscle, and lungs (Table S1). At both 1 and 2 h PI, the tumor,
kidneys, and liver contained the highest concentration of
radioactivity (Figure 3b). At 2 h PI, blood activity had cleared
signiﬁcantly compared to 1 h PI (0.16 ± 0.04 vs 0.84 ± 0.09%
ID g−1, respectively), and in all organs and tissues, decay-
corrected activity was slightly decreased compared to 1 h PI.
Table 1. IC50 Values for [Ga(THP-NCS-RGD)], [Ga(THP-
PhNCS-RGD)], and RGD, Determined Using a Solid-Phase








8.3 ± 1.5 5.2−11.3
[Ga(THP-PhNCS-
RGD)]
4.8 ± 0.6 3.6−5.9
RGD 8.7 ± 1.6 5.5−11.9
Figure 2. Mean concentration response curve for 125I-echistatin
titrated with [Ga(THP-NCS-RGD)] (black), [Ga(THP-PhNCS-
RGD)] (red), and RGD (blue) (n = 6 for each concentration; error
bars correspond to standard error of the mean).
Figure 3. PET imaging and ex vivo biodistribution of (a) [68Ga(THP-NCS-RGD)] and (b) [68Ga(THP-PhNCS-RGD)]. Representative PET
maximum intensity projection of Balb/c nu/nu mice bearing a U87MG tumor on right ﬂank at (i) 1 h PI of tracer, (ii) 1 h after coinjection of tracer
and RGD, and (iii) 2 h PI of tracer, (iv) ex vivo biodistribution in mice at 1 and 2 h PI of tracer, and 1 h PI of tracer coadministered with RGD
(blocked); n = 3. Error bars correspond to standard error of the mean.
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Similarly, PET scans of animals administered [68Ga(THP-
PhNCS-RGD)] demonstrated that [68Ga(THP-PhNCS-
RGD)] accumulated in the tumor, with a tumor to background
concentration ratio of 2.34 ± 0.06, and a tumor to liver
concentration ratio of 0.91 ± 0.03 at 1 h PI. There was no
evidence of bone uptake being above that of surrounding
muscle. Ex vivo biodistribution data demonstrated that there
was signiﬁcantly more activity associated with the tumor for
animals administered solely [68Ga(THP-PhNCS-RGD)] 1 h PI
(2.86 ± 0.43%ID g−1) than for animals coadministered
[68Ga(THP-PhNCS-RGD)] and RGD (0.99 ± 0.12%ID g−1,
mean diﬀerence = 1.87%ID g−1, 95% CI = 0.86−2.89%ID g−1, p
= 6.89 × 10−3), consistent with αvβ3 integrin receptor mediated
tumor uptake. Signiﬁcantly reduced uptake was also observed
for the spleen, liver, and muscle in animals coadministered
RGD (Table S2). In contrast to [68Ga(THP-NCS-RGD)],
uptake of [68Ga(THP-PhNCS-RGD)] in the tumor, spleen,
and liver was slightly higher 2 h PI compared to 1 h PI, while
uptake in other organs decreased (Figure 3b-iv). Blood activity
at 2 h PI (0.25 ± 0.02%ID g−1) was lower than that observed at
1 h PI (0.57 ± 0.03%ID g−1). Blood activity at 1 h PI in the
group coadministered RGD was signiﬁcantly higher (1.29 ±
0.10%ID g−1) than in the group administered only [68Ga(THP-
PhNCS-RGD)] (0.57 ± 0.03%ID g−1) (Table S2).
Tumor uptake of [68Ga(THP-PhNCS-RGD)] was higher
than that of [68Ga(THP-NCS-RGD)] at 1 h PI and 2 h PI (1 h:
2.86 ± 0.43 vs 2.35 ± 0.06%ID g−1, mean diﬀerence = 0.52%ID
g−1, 95% CI = −0.48−1.51%ID g−1, p = 0.22; 2 h: 3.32 ± 0.20
vs 1.90 ± 0.21%ID g−1, mean diﬀerence = 1.41%ID g−1, 95% CI
= 0.75−2.08%ID g−1, p = 4.15 × 10−3, respectively). This is
consistent with the lower IC50 value determined for [Ga(THP-
PhNCS-RGD)] relative to [Ga(THP-NCS-RGD)]. The
observed higher aﬃnity of [Ga(THP-PhNCS-RGD)] (both
in the solid-phase binding assay and in vivo) is possibly a result
of the greater distance between the tris(hydroxypyridinone)
complex and the RGD motif in [68Ga(THP-PhNCS-RGD)]
compared to [68Ga(THP-NCS-RGD)].
Similarly, accumulation of radioactivity in the liver and spleen
is higher in animals administered [68Ga(THP-PhNCS-RGD)]
compared with animals administered 68Ga(THP-NCS-RGD)]
at both 1 and 2 h PI. This diﬀerence in accumulation of the two
tracers in the liver and spleen could be a result of two factors:
(i) the increased αvβ3 integrin aﬃnity of [
68Ga(THP-PhNCS-
RGD)] relative to [68Ga(THP-NCS-RGD)], and/or (ii)
increased nonspeciﬁc uptake of [68Ga(THP-PhNCS-RGD)]
in the liver and spleen compared to [68Ga(THP-NCS-RGD)].
There is some evidence in support of the latterin the
blockade experiments, uptake of [68Ga(THP-PhNCS-RGD)] is
higher than uptake of [68Ga(THP-NCS-RGD)] in both the
liver (2.68 ± 0.12 vs 1.30 ± 0.16%ID g−1) and spleen (0.82 ±
0.03 vs 0.42 ± 0.09%ID g−1).
■ DISCUSSION
Simplicity and eﬃciency of labeling is a key to wider adoption
of 68Ga PET in hospitals. The new bifunctional chelators,
H3THP-NCS and H3THP-PhNCS, enable a facile, single-step
route for preparation of peptide conjugates containing a
tris(hydroxypyridinone) chelator. We chose to attach these
new bifunctional chelators to the αvβ3 integrin-targeting
peptide RGD to evaluate the radiolabeling and biodistribution
proﬁle of a simple tris(hydroxypyridinone) peptide conjugate
and to establish whether such conjugates retain their receptor
targeting aﬃnity in vivo. Conjugation via the pendant
isothiocyanate proceeds under microwave conditions frequently
employed in peptide synthesis.42
The 68Ga-radiolabeling of H3THP-NCS-RGD and H3THP-
PhNCS-RGD could be accomplished at ambient temperatures
simply by addition of acidic solutions of generator-produced
68Ga3+ to solutions of the conjugates, followed by addition of
ammonium acetate. High radiochemical yields (>95%) and
speciﬁc activities (60−80 MBq nmol−1) were achieved,
circumventing the requirement for postsynthetic puriﬁcation.
These uniquely eﬃcient, simple, and mild radiolabeling
properties would aﬀord exceptionally rapid radiochemical
synthesis of a 68Ga radiopharmaceutical and are conducive to
translation to a one-step, kit-based preparation of a peptidic
68Ga-labeled radiotracer based on a tris(hydroxypyridinone)
conjugate.
Serum and metabolic stability data indicate that both
[68Ga(THP-NCS-RGD)] and [68Ga(THP-PhNCS-RGD)] are
stable to 68Ga3+ transchelation to serum proteins, as well as
degradation or modiﬁcation of the conjugates while in
circulation, respectively. Furthermore, PET scans and ex vivo
biodistribution data in Balb/c nu/nu mice bearing glioblastoma
U87MG αvβ3 integrin-positive tumors indicate that both
[68Ga(THP-NCS-RGD)] and [68Ga(THP-PhNCS-RGD)] re-
tain aﬃnity for αvβ3 integrin receptors in vivo. Ex vivo
biodistribution data are consistent with the expression proﬁle of
αvβ3 integrin, which is expressed in tumors including late stage
glioblastomas, angiogenesis,43 and at low levels in normal
vascular tissue.40
Animals coadministered RGD demonstrate that RGD
eﬀectively blocks αvβ3 integrin receptor binding by both
[68Ga(THP-NCS-RGD)] and [68Ga(THP-PhNCS-RGD)] in
tumors, and as such, tumor uptake of the new radiotracers is
receptor-mediated. Biodistribution data also indicate signiﬁcant
receptor-mediated uptake in the liver and spleen for both
radiotracers, and in the heart, muscle, and lungs for
[68Ga(THP-NCS-RGD)]. Similar decreased uptake in blockade
experiments for the liver, spleen, heart, lungs, muscles, adrenals,
and intestines has been previously observed with other RGD
conjugates labeled with PET isotopes 68Ga, 64Cu, 18F, and
44Sc.19,20,26,27,44,45 Tumor uptake of [68Ga(THP-NCS-RGD)]
(1 h: 2.35 ± 0.06%ID g−1, 2 h: 1.90 ± 0.21%ID g−1) and
[68Ga(THP-PhNCS-RGD)] (1 h: 2.86 ± 0.43, 2 h: 3.32 ±
0.20) is comparable to that of other conjugates of RGD
reported in U87MG tumor bearing mice, although generally
tumor to nontarget organ ratios, notably the liver, are lower for
the tris(hydroxypyridinone) conjugates. 68Ga-labeled conju-
gates of RGD demonstrate receptor-mediated tumor uptake at
1 h PI of 5.19 ± 1.45%ID g−1 for 68Ga-NODAGA-RGD and
3.47 ± 0.78%ID g−1 for 68Ga-DOTA-RGD. Similar accumu-
lation is observed for 64Cu-labeled analogs.20 The 18F-galacto-
RGD PET tracer has an uptake of 1.16%ID g−1 1 h PI, but
signiﬁcantly lower nontarget organ uptake.46 The dimeric
conjugate containing two αvβ3 integrin targeting cyclic-
(RGDyK) groups, 68Ga-NODAGA-E(RGDyK)2, demonstrates
receptor mediated accumulation, with U87MG tumor uptake
measuring 2.23 ± 0.08%ID g−1 1 h PI and liver uptake of 2.97
± 0.39%ID g−1,19 values comparable to the monomeric tracers
described here.
■ CONCLUDING REMARKS
The new bifunctional chelators, H3THP-NCS and H3THP-
PhNCS, enable a facile route for preparation of conjugates
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.5b00335
Bioconjugate Chem. 2016, 27, 309−318
313
containing a tris(hydroxypyridinone) chelator, and the
conjugates retain the uniquely eﬃcient radiolabeling properties
reported for the maleimide derivative,36 aﬀording exceptionally
rapid radiochemical synthesis of a 68Ga radiopharmaceutical
under mild conditions without the need for subsequent
puriﬁcation. Ga3+-complexed conjugates of RGD retain aﬃnity
for αvβ3 integrin receptors, and provide PET images that allow
clear delineation of αvβ3 integrin-positive tumors. The
eﬃciency of labeling tris(hydroxypyridinone) chelators at very
low concentrations and under mild conditions brings the
possibility of kit-based production of 68Ga PET tracers,
including sensitive proteins, without complex automated
synthesis typical of multistep PET radiochemistry. This would
greatly increase 68Ga PET access to hospitals that lack expertise
or facilities to implement such automated synthetic technolo-
gies but are adept in preparation of kit-based radiopharmaceu-
ticalsnotably radiopharmacy laboratories routinely producing
99mTc radiopharmaceuticals. Thus, such kit-based technologies
will expand the use of the 68Ga generator for the beneﬁt of
more hospitals and patients.
■ EXPERIMENTAL PROCEDURES
Materials and Instrumentation. Chemicals and reagents
were obtained from Sigma-Aldrich (Dorset, UK) unless
otherwise speciﬁed. High-performance liquid chromatography
(HPLC) analysis was carried out using an Agilent 1200 LC
system with in-line UV and gamma detection (Flow-Count,
LabLogic). NMR spectra were acquired on a Bruker Avance
400 spectrometer (Bruker UK Limited, Coventry, UK)
equipped with a 5 mm QNP probe at 400.13 MHz for 1H
NMR spectra (using a zg30 pulse program) and 100.6 MHz for
13C NMR spectra (using a zgpg30 pulse program). Spectra
were referenced to residual solvent signals. Mass spectra were
recorded in the positive ion mode on an Agilent 6510 Q-TOF
LC/MS mass spectrometer coupled to an Agilent 1200 LC
system (Agilent, Palo Alto, CA). Data were acquired and
reference mass-corrected via a dual-spray electrospray ioniza-
tion source, using the factory-deﬁned calibration procedure.
Analytical reverse-phase LCMS and radio-LCMS traces were
acquired using an Eclipse XDB-C18 column (4.6 × 150 mm, 5
μm) with a 1 mL min−1 ﬂow rate. Instant thin layer
chromatography strips (ITLC-SG) were obtained from Varian
Medical Systems UK, Ltd. (Crawley, UK), and ITLC strips
were visualized using a Raytest Rita-Star TLC scanner.
Semipreparative reverse-phase HPLC was conducted using an
Agilent Eclipse XDB-C18 column (9.4 × 250 mm, 5 μm)
coupled to an Agilent 1200 LC system, with a 3 mL min−1 ﬂow
rate and UV spectroscopic detection at 220 nm. Mobile phase
A contained water with 0.2% TFA and mobile phase B
contained acetonitrile with 0.2% TFA. All methods started with
100% A at 0 min. For method 1, the concentration of B
increased at a rate of 1% min−1, and for method 2, the
concentration of B increased at a rate of 0.5% min−1. Analytical
reverse-phase HPLC and radio-HPLC traces were acquired
using two diﬀerent instruments: (1) an Agilent 1200 LC system
and an Agilent Zorbax Eclipse XDB-C18 column (4.6 × 150
mm, 5 μm) with a 1 mL min−1 ﬂow rate and UV spectroscopic
detection at either 214 or 220 nm. The radio-HPLC was
coupled to a LabLogic Flow-Count detector with a sodium
iodide probe (B-FC-3200). Aliquots (10−200 μL) of each
radiolabeled sample were injected onto the column, using a
ﬂow rate of 1 mL min−1. Mobile phase A contained water with
0.1% TFA and mobile phase B contained acetonitrile with 0.1%
TFA. For method 3, the concentration of B increased at a rate
of 5% min−1, with 100% A at 0 min, and 100% B at 20 min. (2)
An Agilent Zorbax Eclipse XDB-C18 column (4.6 × 150 mm, 5
μm) with a 1 mL min−1 ﬂow rate and UV spectroscopic
detection at either 214 or 220 nm coupled to a Shimadzu
HPLC consisting of a SCL-10AVP system controller, a SIL-
10ADVP autoinjector, a LC-10 ATVP solvent delivery unit, a
FCV-10AL control valve, a DGU-14A degasser, and a SPD-
10AVP UV detector. This was coupled to a radiation detector
consisting of an Ortec model 276 Photomultiplier Base with
Preampliﬁer, Ampliﬁer, BIAS supply and SCA and a Bicron 1
M 11.2 Photomultiplier Tube. For method 4, the concentration
of B increased at a rate of 6.67% min−1, with 100% A at 0 min,
and 80% B at 12 min. For initial radiolabeling and
characterization studies that utilized <400 MBq, an Eckert
and Ziegler 68Ge/68Ga generator (Berlin, Germany) was used.
For biodistribution studies, and experiments that utilized >600
MBq 68Ga, an iThemba Laboratories 1.8 GBq 68Ge/68Ga
generator (IDB Holland BV, Netherlands) was used. Analytical
size exclusion radio-HPLC traces were acquired using an
Agilent 1200 Series HPLC system and a Phenomenex Biosep
2000 (300 × 7.8 mm) size exclusion column with a phosphate
buﬀered saline mobile phase with a ﬂow rate of 1 mL min−1.
Synthesis. Compound 2. Compound 1 (synthesized
according to previously reported procedures38) (100 mg, 96
μmol) was dissolved in ethanol (5 mL), and carbon disulﬁde
(60 μL, 12 equiv) and triethylamine (13.4 μL, 1 equiv) were
added.39 Addition of water (5 mL) resulted in formation of a
white precipitate, corresponding to the dithiocarbamate
intermediate. Excess carbon disulﬁde was removed under
reduced pressure, and the remaining solution frozen and
lyophilized. The dry residue was resuspended in ethanol (5
mL) containing carbon disulﬁde (60 μL) and triethylamine
(13.4 μL). Di-tert-butyl dicarbonate (4 equiv, 21 mg) and 4-
dimethylaminopyridine (2−3% molar equiv) were added,39 and
the reaction stirred at room temperature for 6 h. The reaction
mixture was evaporated to dryness, the residue dissolved in
water/acetonitrile (60%/40%) and applied to a semipreparative
reverse-phase Agilent Eclipse XDB-C18 column (9.4 × 250
mm, 5 μm) with a 3 mL min−1 ﬂow rate and UV spectroscopic
detection at 220 nm. Using HPLC method 1, 1 eluted with
40% B (40 min). Fractions containing the desired product were
lyophilized. Yield = 50 mg, 48%. 1H NMR ((CD3)3SO, 400
MHz): δ 1.80 (m, 6H), 2.05 (m, 6H), 2.45 (t, J = 6.37, 2H),
2.55 (s, 9H), 3.75 (broad, 2H), 3.75 (s, 9H), 4.53 (d, J = 5.06,
6H), 5.13 (s, 6H), 7.13 (s, 3H), 7.35−7.48 (m, 15H + NH),
8.30 (t, J = 5.06, 3NH). 13C NMR ((CD3)3SO, 100 MHz): δ
20.4, 28.9, 29.6, 34.5, 35.4, 38.5, 41.1, 56.6, 74.0, 114.6, 127.5,
128.1, 128.2, 128.3, 136.1, 142.9, 146.3, 151.5, 165.0, 167.9,
171.2. ESI-MS: m/z for C59H68N8O10S + H
+ calc 1081.48,
found 1081.48.
H3THP-NCS. A solution of chilled boron trichloride in
dichloromethane (10 mL, 1 M) was added to a sealed vial
containing compound 2 (46 mg, 43 μmol), and the reaction
was stirred at ambient temperature for 1 h. The reaction vial
was then cooled in an ice bath, and triﬂuoroethanol (3 mL) was
added dropwise to the ﬂask. The reaction solution was
evaporated to dryness, and the residue dissolved in water/
acetonitrile (80%/20%) and ﬁltered. The ﬁltrate was diluted to
10 mL using a solution of 0.2% TFA in water, and applied to a
semipreparative HPLC column. Using HPLC method 2,
H3THP-NCS eluted with 17−18% B (37 min). Fractions
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containing the desired product were lyophilized. Yield of
triﬂuoroacetate salt = 25 mg, 47% yield. 1H NMR ((CD3)3SO,
400 MHz): δ 1.82 (m, 6H), 2.08 (m, 6H), 2.45 (t, J = 6.41 2H),
2.52 (s, 9H), 3.77 (t, J = 6.41, 2H), 3.80 (s, 9H), 4.54 (d, J =
5.21, 6H), 6.97 (s, 3H), 7.43 (s, 1NH), 8.47 (t, J = 5.21, 3NH).
13C NMR ((CD3)3SO, 100 MHz): δ 20.3, 25.5, 28.8, 34.4, 35.4,
38.3, 41.1, 57.0, 112.4, 127.8, 138.6, 143.2, 148.3, 160.9, 168.2,
173.1. ESI-MS: m/z for C38H50N8O10S + H
+ calc 811.34, found
811.36.
Compound 3. An excess of p-phenylene diisothiocyanate
(40 mg) and diisopropylethylamine (40 μL) in DMF (0.5−1
mL) were added to a solution of 1 (40 mg, 39 μmol) in DMF
(0.5−1 mL). The reaction solution was agitated, and after 5−10
min, applied to a semipreparative HPLC column. Using HPLC
method 1, 3 eluted with 42% B (42 min). Fractions containing
the desired product were lyophilized. Yield = 39 mg, 81% yield.
1H NMR (CD3OD, 400 MHz): δ 1.94 (m, 6H), 2.15 (m, 6H),
2.46 (t, J = 6.14, 2H), 2.60 (s, 9H), 3.79 (broad, 2H), 3.84 (s,
9H), 4.60 (s, 6H), 5.20 (s, 6H), 7.17 (d, J = 8.79, 2H), 7.33−
7.46 (15H), 7.41 (d, J = 8.79, 2H). 13C NMR (CD3OD, 100
MHz): δ 21.4, 30.7, 31.0, 36.5, 36.9, 39.9, 42.1, 59.1, 76.3,
116.2, 125.7, 127.1, 128.6, 129.7, 129.9, 130.0, 136.6, 137.5,
145.0, 148.4, 154.1, 166.6, 173.6, 175.4, 182.0. ESI-MS: m/z for
C66H74N10O10S2 + 2H
+ calc 616.26, found 616.26.
H3THP-PhNCS. A solution of chilled boron trichloride in
dichloromethane (5 mL, 1 M) was added to a sealed vial
containing compound 3 (20 mg, 16 μmol), and the reaction
was stirred at ambient temperature for 1 h. The reaction vial
was then cooled in an ice bath, and methanol (5−10 mL) was
added dropwise to the ﬂask. The reaction solution was
evaporated to near dryness under reduced pressure, and
acetone (50 mL) was added to the residue, resulting in a
ﬂocculant white precipitate. This suspension was transferred to
a 50 mL centrifugal tube, and the mixture centrifuged at 3000
rpm for 10 min. After this, the solution was decanted and
discarded, acetone added (50 mL), the suspension agitated, and
centrifuged again for 10 min. This process of washing with
acetone was repeated again. Finally, the product was dissolved
in water/acetonitrile (50/50), ﬁltered, frozen and lyophilized.
Yield = 10 mg, 58% yield. 1H NMR (CD3OD, 700 MHz): δ
1.98 (m, 6H), 2.22 (m, 6H), 2.49 (t, J = 6.13 2H), 2.59 (s, 9H),
3.82 (broad, 2H), 3.93 (s, 9H), 4.69 (s, 6H), 7.00 (s, 3H), 7.23
(d, J = 8.44, 2H), 7.43 (d, J = 8.44, 2H). 13C NMR (CD3OD,
175 MHz): δ 21.1, 30.6, 31.0, 36.3, 36.9, 39.5, 42.2, 59.1, 114.1,
125.8, 127.2, 128.8, 136.8, 139.4, 140.0, 145.2, 150.4, 162.2,
173.6, 176.3, 182.1. ESI-MS: m/z for C45H56N10O10S2 + H
+ calc
961.37, found 961.37.
Synthesis of RGD Conjugates. The cyclic peptide cyclic-
(RGDfK) (RGD) was dissolved in dimethyl sulfoxide (100−
300 μL) and added to a solution of either H3THP-NCS or
H3THP-PhNCS in dimethyl sulfoxide (100−300 μL), and
diisopropylethylamine (5−10 μL) was added. The reaction
solutions were heated in a microwave (120 °C, 300 W, 30 min)
and then applied to a reverse-phase HPLC column. Fractions
containing the desired conjugate in suﬃcient purity were
combined and lyophilized. Using HPLC method 2, H3THP-
NCS-RGD eluted with 21% solvent B (42 min) and H3THP-
PhNCS-RGD eluted with 23% solvent B (47 min). Isolated
yields = 30−40%. H3THP-NCS-RGD: ESI-MS: m/z for
C65H91N17O17S + 3H
+ calc 472.22, found 472.22; HPLC: 220
nm, RT = 7.15 min, >98% purity (HPLC method 3). H3THP-
PhNCS-RGD: ESI-MS: m/z for C72H97N19O17S2 + 3H
+ calc
522.23, found 522.24; HPLC: 220 nm, RT = 7.80 min, >98%
purity (HPLC method 3).
Complexing H3THP-NCS-RGD and H3THP-PhNCS-RGD
with 68Ga3+ and natGa3+. Initial radiolabeling experiments
utilized an Eckert & Ziegler 68Ge/68Ga generator. Aqueous HCl
solution (0.1 M, 5 mL) was passed through the generator and
the eluate was fractionated (5 × 1 mL). The second fraction (1
mL, containing 90−100 MBq 68Ga) was added directly to an
ethanol/water solution (50%/50%, 50−100 μL) of either
H3THP-NCS-RGD (22.5 μg) or H3THP-PhNCS-RGD (25
μg), immediately followed by a solution of ammonium acetate
(1 M, 300 μL). This solution was immediately applied to an
analytical reverse-phase C18 HPLC column. [68Ga(THP-NCS-
RGD)]: radiochemical yield >99% (HPLC), HPLC: RT = 7.83
min (HPLC method 3). [68Ga(THP-PhNCS-RGD)]: radio-
chemical yield >99% (HPLC), HPLC: RT = 8.15 min (HPLC
method 3). For both conjugates, speciﬁc activity at calibration =
8−9 MBq nmol−1 conjugate.
The nonradioactive analogues, [natGa(THP-NCS-RGD)]
and [natGa(THP-PhNCS-RGD)], were also prepared. An
aqueous solution of GaCl3 (2 mg mL
−1, 5 μL, 50−60 nmol)
was added to either H3THP-NCS-RGD (45 μg, ∼24 nmol) or
H3THP-PhNCS-RGD (50 μg, ∼25 nmol) dissolved in
deionized water (50 μL). The solutions were applied to an
analytical reverse-phase C18 HPLC column and subjected to
LCMS analysis. [natGa(THP-NCS-RGD)]: HPLC RT = 7.57
min (HPLC method 3); MS C65H88N17O17SGa + 2H
+,
observed monoisotopic peak = 740.78, calculated =740.78.
[natGa(THP-PhNCS-RGD)]: HPLC RT = 8.15 min (HPLC
method 3); MS C72H94N19O17S2Ga + 2H
+, observed
monoisotopic peak = 815.80, calculated 815.80.
For biodistribution studies, 68Ga eluate from an iThemba Lab
generator was preconditioned as previously described.41 Brieﬂy,
a cation exchange cartridge containing AG 50W×4 resin (50
mg) was conditioned by passing through aqueous HCl solution
(4 M, 1 mL) and deionized water (1 mL) sequentially. To elute
the 68Ge/68Ga generator, aqueous HCl solution (0.4 M, 5 mL)
was passed through the generator and transferred directly onto
the cation exchange cartridge. The cartridge was dried with air
(1 mL), washed with 0.15 M HCl in water/ethanol (20%/
80%), and again dried with air (1 mL). A solution of 0.9 M HCl
in water/ethanol (200 μL, 10%/90%) was used to elute 68Ga
(800−1000 MBq), which was diluted to a volume of 1 mL with
deionized water. Lyophilized peptide conjugateH3THP-
NCS-RGD (22.5 μg, triﬂuoroacetate salt) or H3THP-PhNCS-
RGD (25 μg, triﬂuoroacetate salt)dissolved in 20−40 μL of
water/ethanol (50%/50%) was added to the solution
containing 68Ga, immediately followed by a solution of
ammonium acetate (2 M, 400 μL) and 0.9% saline (1100
μL). An aliquot for ITLC analysis was immediately applied to
an ITLC-SG plate. The ITLC-SG plate was developed using an
aqueous citrate buﬀer (0.1 M, pH 5.5) mobile phase.
[68Ga(THP-NCS-RGD)] and [68Ga(THP-PhNCS-RGD)]: Rf
< 0.1; [68Ga(citrate)2]
3−: Rf > 0.8. [
68Ga(THP-NCS-RGD)]:
radiochemical yield = 96−98% (ITLC), HPLC: RT = 9.42 min
(HPLC method 4). [68Ga(THP-PhNCS-RGD)]: radiochemical
yield = 97−99% (ITLC), HPLC: RT = 9.78 min (HPLC
method 4). For both conjugates, speciﬁc activity at dose
measurement = 60−80 MBq nmol−1 conjugate.
Serum Stability Studies. Solutions containing [68Ga-
(THP-NCS-RGD)] and [68Ga(THP-PhNCS-RGD)] (each
250 μL, containing 50 MBq 68Ga3+ and ∼5 μg of peptide
conjugate, synthesized using eluate from an Eckert and Ziegler
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generator as described above) were added to 1.25 mL of fresh
human female O+ serum, and incubated at 37 °C for 4 h. At 1
and 4 h, aliquots were applied to a size exclusion HPLC
column. Solutions of [68Ga(THP-NCS-RGD)] and [68Ga-
(THP-PhNCS-RGD)] were also separately subjected to size
exclusion chromatographic analysis to determine retention
times. A solution of 68Ga3+ in 0.33 M ammonium acetate (10
MBq, 50 μL) was added to 250 μL of serum and incubated at
37 °C for 1 h to determine the retention time of 68Ga3+-bound
serum proteins.
Metabolic Stability Studies. Solutions containing [68Ga-
(THP-NCS-RGD)] and [68Ga(THP-PhNCS-RGD)] (synthe-
sized using eluate from an Eckert and Ziegler generator as
described above) were diluted with physiological saline solution
(15−30 MBq of each radiotracer containing 1−3 μg conjugate)
and administered intravenously to seven- to nine-week-old
female Balb/c mice (Harlan, UK) under isoﬂurane anesthesia.
At 20 or 90 min PI, animals were euthanized, and serum and
urine samples collected and analyzed using analytical reverse-
phase HPLC (method 3).
Determination of IC50. The relative aﬃnity of [Ga(THP-
NCS-RGD)], [Ga(THP-PhNCS-RGD)], and RGD for integrin
αvβ3 was determined in a solid-phase competitive binding
assay45,47 with 125I-echistatin (PerkinElmer, Boston). In brief,
wells of a 96 well plate were coated with integrin αvβ3 (150 ng
mL−1) in coating buﬀer (100 μL, 25 mM Tris HCl pH 7.4, 150
mM NaCl, 1 mM CaCl2, 0.5 mM MgCl2, and 1 mM MnCl2)
overnight at 4 °C. Wells were then washed twice in binding
buﬀer (coating buﬀer containing 0.1% bovine serum albumin
(w/v) (BSA)) before being blocked for 2 h at room
temperature with blocking buﬀer (coating buﬀer containing
1% BSA (w/v)). After a further two washes in binding buﬀer,
125I-echistatin (0.5 kBq) and [Ga(THP-NCS-RGD)], [Ga-
(THP-PhNCS-RGD)], or RGD were added simultaneously (to
a total volume of 100 μL, and a conjugate/(RGDfK)
concentration of 10 000 nM to 0.001 nM) for 1 h at room
temperature, before being washed twice as before. Finally, the
amount of activity bound to the wells via integrin αvβ3 was
counted using a Wallac 1282 Compugamma Universal Gamma
Counter. Measurements at each concentration for each
compound were obtained in sextuplicate. IC50 values were
calculated using a nonlinear regression model (Binding/
Saturation, one site−total) in GraphPad Prism 5.04.
PET Scanning and Biodistribution. All animal experi-
ments were performed with approval from the Peter
MacCallum animal ethics committee. Six- to eight-week-old
Balb/c nude mice (Animal Resources Centre, Western
Australia) were implanted subcutaneously on the right ﬂank
with 4 million U87MG cells. Once the tumors reached a
volume of >250 mm3 the animals were injected intravenously
with 13−20 MBq [68Ga(THP-NCS-RGD)] (containing 1 μg of
H3THP-NCS-RGD). For blocking studies, animals were
coinjected with RGD peptide (400 μg). At 1 and 2 h, the
animals were anaesthetized and imaged on a Philips MOSAIC
small animal PET scanner. The images were reconstructed
using a 3D RAMLA algorithm and tracer uptake determined as
described previously.48 On completion of the scan animals were
euthanized and tissues harvested, weighed, and radioactivity
counted using a Gamma Counter (Biomedex).
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